Infectious Disease Point-of-care (POC) Diagnostics Market was valued at USD 15.81 Billion by 2022; Trinity Biotech Partnered with imaware Inc. to Enhance the Digital Health Industry with At-Home and Remote Testing Programs: Fortune Business Insights™

The global infectious disease point-of-care (POC) diagnostics market size was valued at USD 15.81 billion in 2022. The market is anticipated to decline from USD 15.21 billion in 2023 to USD 12.46 billion by 2030, exhibiting a CAGR of -2.8% over the estimated period. Infectious Disease Point-of-care (POC) Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Technique (Lateral Flow Immunoassay, Agglutination Test, Flow-through Test, Molecular Diagnostics, and Others), By Disease (HIV, Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), Influenza, Clostridium Difficile Infections (CDI), Hepatitis C Virus, Methicillin-Resistant Staphylococcus Aureus (MRSA), Tuberculosis, and Others), By Disease, COVID-19 Point-of-care (POC) Diagnostics, By End User (Hospital Bedside, Physicians Office Lab, Urgent Care & Retail Clinics, Home & Self-Testing, Nursing Homes, and Others), and Regional Forecast, 2023-2030. 

The rising emphasis on the introduction of POC platforms and tests based on nanodevices and nanoparticles is expected to boost the market growth.

Introduction of Advanced Products During COVID-19 to Propel Market Growth

The COVID-19 had a notable impact on the infectious disease point-of-care (POC) diagnostics market growth. As the world grappled with the pandemic, the need for advanced POC diagnostic kits was at its peak due to their ability to detect the SARS-CoV-2 virus and provide accurate results. The rapid development and deployment of advanced testing solutions surged the demand for POC products to a great extent during the pandemic.

However, demand and sales for diagnosis products related to infectious diseases such as HIV (Human Immunodeficiency Virus), CDI (Clostridium difficile infection), and MRSA (methicillin-resistant Staphylococcus aureus) declined due to the imposition of lockdown measures and disruptions in the supply chain.

Trinity Biotech Gained The Approval For Trinscreen HIV

In February 2022, Trinity Biotech gained the approval for its HIV screening product called TrinScreen HIV from World Health Organization (WHO). The test offers rapid results in than 12 minutes using a finger stick drop of blood. The launch of the product is expected to increase the company’s presence in the market.

Shift From Centralized Testing to Decentralized POC Testing to Boost Infectious Disease Point-Of-Care (PoC) Diagnostics Demand

One significant trend in infectious disease point-of-care (POC) diagnostics market is the shift from centralized testing to decentralized POC testing for infectious diseases, which improves patient care by offering faster results, thereby surging the demand for diagnostic tests.

However, the industry expansion may be hindered due to the lack of training among clinicians, especially in developing countries.

Key Players Focusing on Various Strategies to Increase Geographical Footprint

Companies operating in the region are focusing on collaborating and forming partnerships to leverage each other's strengths and resources. These collaborations accelerate product development, expand market reach, and enhance competitiveness. Simultaneously, substantial investments in research and development (R&D) drive innovation, resulting in advanced infectious disease point-of-care (POC) diagnostics.

Key Industry Development:

• January 2023- Trinity Biotech, announced a strategic partnership with imaware Inc. To power the digital health industry with at-home and remote testing programs, the company introduced advanced reference laboratory facilities integrated with diagnostic testing solutions.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/infectious-disease-point-of-care-poc-diagnostics-market-104307

List of Key Players Mentioned in the Report:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott Laboratories (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• BD (U.S.)
•  bioMérieux SA (France)
• Cardinal Health, Inc. (U.S.)
• Cepheid (U.S.)
• Trinity Biotech (Ireland)
•  Quidel Corporation (U.S.)
• Bio-Rad Laboratories Inc. (U.S)

Further Report Findings:

• The infectious disease point-of-care (POC) diagnostics market share in the North American region held a key position in the global market. The formation of strategic partnerships among industry players and governmental organizations with a focus on developing rapid diagnostic tests has bolstered the adoption of point-of-care diagnostics for infectious diseases.
• The European market for infectious disease point-of-care (POC) diagnostics is likely to expand at a substantial pace over the forecast period. This expansion is driven by the growing strategic alliances and partnerships among key players in the industry. These collaborations have led to the development and expansion of innovative POC diagnostic solutions for infectious diseases, driving market growth.
• In terms of disease, the market for infectious disease point-of-care (POC) diagnostics is divided into clostridium difficile infections (CDI), respiratory syncytial virus, influenza, MRSA, hepatitis C virus, hepatitis B virus, tuberculosis, HIV, pneumonia/streptococcus-associated infections, and others. The clostridium difficile infections (CDI) segment dominated due to the substantial sales volume of point-of-care (POC) kits for CDI diagnosis. The high demand for these kits is driven by the global incidence rate of CDI and the need for accurate and rapid diagnosis.

Table of Segmentation